Celldex Therapeutics (CLDX) Cash & Equivalents (2010 - 2026)

Celldex Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 108.5% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $35.7 million (up 108.5% YoY), while the FY2025 annual figure was $28.9 million, up 1.82% from the prior year.
• Cash & Equivalents was $35.7 million for Q1 2026 at Celldex Therapeutics, up from $28.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $115.1 million in Q1 2024 to a low of $17.1 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $35.5 million across 5 years, with a median of $28.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 113.98% in 2023, then sank 85.11% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $29.4 million in 2022, then advanced by 18.3% to $34.8 million in 2023, then dropped by 18.55% to $28.4 million in 2024, then grew by 1.82% to $28.9 million in 2025, then gained by 23.75% to $35.7 million in 2026.
• The last three Cash & Equivalents figures came in at $35.7 million (Q1 2026), $28.9 million (Q4 2025), and $36.0 million (Q3 2025), per Business Quant data.